US and European regulators have accepted filings for Novartis’s siponimod for secondary progressive multiple sclerosis (SPMS). The US Food and Drug Administration (FDA) and European Medicines ...
The FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a potential blow to a much-delayed rival from Celgene. Mayzent’s approval ...
The following is a summary of “Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with ...
Read the Medication Guide provided by your pharmacist before you start taking siponimod and each time you get a refill. If you have any questions, ask your doctor or pharmacist. Take this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback